Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7039395 | 1.00 | CTSB (0.46) | CTSBALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL7039392 | 1.00 | CTSB (0.46) | CTSBALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL10414186 | 0.80 | CTSK (0.53) | CTSBALDH1A1ATMCTRB1 | |
| SCHEMBL6963650 | 0.77 | ALDH1A1 (0.55) | CTSBALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL22692566 | 0.77 | ALDH1A1 (0.58) | CTSBALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL31153792 | 0.76 | ALDH1A1 (0.46) | CTSBALDH1A1ATMHCAR2 | |
| SCHEMBL5674461 | 0.76 | ALDH1A1 (0.43) | CTSBALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL6963655 | 0.76 | ALDH1A1 (0.56) | CTSBALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL6982935 | 0.76 | ALDH1A1 (0.56) | CTSBALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL12264780 | 0.76 | ALDH1A1 (0.56) | CTSBALDH1A1MAPTHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069091-A9 | Oxazinones and methods for their use and synthesis | CHIROLOGIX PHARMACEUTICALS, INC. | 2006-03-30 | — | — | US | disclosed |
| US-20050124612-A1 | Oxazinones and methods for their use and synthesis | CHIROLOGIX PHARMACEUTICALS, INC. | 2005-06-09 | — | — | US | disclosed |
| US-6861416-B2 | Oxazinones and methods for their use and synthesis | CHIROLOGIX PHARMACEUTICALS, INC. (CA) | 2005-03-01 | — | — | US | disclosed |
| US-20040023956-A1 | New intermediates and synthetic methods for the stereospecific synthesis of oxazinone compounds, which are useful, for example, as antibiotics. The invention also pertains to novel olefinic oxazinone compounds, methods for | CHIROLOGIX PHARMACEUTICALS, INC (CA) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069091-A9 | Oxazinones and methods for their use and synthesis | DHPS, COASY, SQLE | CTSB 1921/4885ALDH1A1 584/4885MAPT 3793/4885 |
| US-20050124612-A1 | Oxazinones and methods for their use and synthesis | DHPS, COASY, SQLE | CTSB 1921/4885ALDH1A1 584/4885MAPT 3793/4885 |
| US-20040023956-A1 | New intermediates and synthetic methods for the stereospecific synthesis of oxazinone compounds, which are useful, for example, as antibiotics. The invention also pertains to novel olefinic oxazinone compounds, methods for | SQLE, DHPS, COASY | CTSB 1929/4885ALDH1A1 648/4885MAPT 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.